Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

Antimicrobial Agents and Chemotherapy
M NakashimaH Uchida

Abstract

The pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, was examined in healthy male volunteers after the oral administration of a single dose of 100, 200, 400, or 600 mg and multiple doses of 300 mg twice daily for 6.5 days (13 total doses). Throughout the whole study period, AM-1155 was well tolerated in every subject. In the single-dose study, the concentrations in serum reached a peak between 1 and 2 h, and the peak concentrations were 0.873, 1.71, 3.35, and 5.41 micrograms/ml at the doses of 100, 200, 400, and 600 mg, respectively. The elimination half-life was 7 to 8 h, independently of the doses. The unchanged drug was excreted mainly in the urine, with 82 to 88% of the doses appearing for 72 h. The fecal recovery of the unchanged drug amounted to 5.7% for 72 h after a single oral administration of a 400-mg dose. Urinary excretion of metabolites was minimal. The serum protein binding was 20%, independently of the concentrations in serum. The concentrations in saliva were approximately 80% of those in serum. The intake of food had no effect on the pharmacokinetic parameters and urinary excretion of AM-1155 except the slight decrease in area under the concentration-time curve. The concurrent administration of ...Continue Reading

References

Oct 1, 1992·Antimicrobial Agents and Chemotherapy·M HosakaK Hirai
Mar 1, 1991·Antimicrobial Agents and Chemotherapy·G R GrannemanA G Pernet
Jan 1, 1990·Antimicrobial Agents and Chemotherapy·K ShibaT Ooie
Jan 1, 1989·Clinical Pharmacokinetics·F SörgelU Stephan
Jan 1, 1986·Chemotherapy·S B ThorsteinssonR Holm
Oct 1, 1988·The Journal of Antimicrobial Chemotherapy·M NakashimaH Uchida
Oct 1, 1988·Antimicrobial Agents and Chemotherapy·J W StoneR Wise
Mar 1, 1994·Antimicrobial Agents and Chemotherapy·E Wakabayashi, S Mitsuhashi

❮ Previous
Next ❯

Citations

Dec 29, 2000·Comprehensive Therapy·M Gotfried, C Freeman
Sep 11, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Hoang Anh NguyenMarie-Claude Saux
Sep 13, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G H McCracken
Sep 13, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M Grasela
Jul 1, 2009·The Journal of Infectious Diseases·Bruno FantinFrance Mentré
Sep 3, 1999·The Journal of Antimicrobial Chemotherapy·S L PendlandC A Schriever
Dec 10, 1999·The Journal of Antimicrobial Chemotherapy·P M Roblin, M R Hammerschlag
Feb 25, 2009·Critical Care Medicine·Jason A Roberts, Jeffrey Lipman
Jan 16, 2007·Antimicrobial Agents and Chemotherapy·Christopher M RubinoDennis M Grasela
Jul 1, 2009·Antimicrobial Agents and Chemotherapy·Cornelia B LandersdorferFritz Sörgel
Nov 23, 2011·Antimicrobial Agents and Chemotherapy·Kazumasa YokoyamaYasuhiko Suzuki
May 23, 2002·Antimicrobial Agents and Chemotherapy·D Andes, W A Craig
Oct 27, 2011·BMC Infectious Diseases·Carlos Rv Kiffer, Antonio Cc Pignatari
Jul 2, 2003·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Masaki Hosaka
Feb 24, 2001·Pharmacotherapy·D N Fish, D S North
Oct 20, 2001·Pharmacotherapy·K A Rodvold, M Neuhauser
Apr 8, 2004·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Ming GuoQing-Sen Yu
May 1, 2001·Clinical Pharmacokinetics·A AminimanizaniR Jelliffe
Mar 15, 2005·Clinical Pharmacokinetics·Vincent Launay-VacherGilbert Deray
May 21, 2011·Dental Materials Journal·Gaku TamazawaTazuko Satoh
Jun 14, 2006·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Ming Guo, Qing-Sen Yu
Mar 25, 1999·Clinical Therapeutics·J M Blondeau
Jun 10, 2014·Drug Metabolism Reviews·Jayaprakasam BolleddulaDavid L Bourdet
Mar 23, 2012·Expert Opinion on Drug Metabolism & Toxicology·Aditi MulgaonkarDouglas H Sweet
Nov 4, 2000·Expert Opinion on Investigational Drugs·J M Blondeau

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.